Detecting off-target effects is a crucial part of drug development and safety assessment. This is typically achieved through a combination of in vitro assays, in vivo studies, and computational modeling. High-throughput screening can identify potential off-target interactions by testing a compound against a wide array of biological targets. Computational models might predict off-target effects based on the drug's structure and known biological interactions. Clinical trials then provide data on adverse effects in humans.
